Alembic Pharma Q2 FY27 Revenue Surges 36% YoY to ₹2,603 Crore; PAT Jumps 81%
Alembic Pharmaceuticals reported Q2 FY27 revenue of ₹2,603 crore, up 36% YoY. PAT surged 81% YoY to ₹335 crore. US business grew 77% YoY, and India Branded Business rose 14% YoY. Total revenue for H1 FY27 was ₹4,753 crore, up 31% YoY.
The substantial increase in revenue and profit, driven by strong growth in major markets like the US and India, is expected to have a significant positive impact on the company's financial standing.
The company reported significant year-on-year growth in revenue and profit, alongside strong performance across its key business segments.
Alembic Pharmaceuticals Limited announced its unaudited financial results for the quarter and half-year ended September 30, 2026. The company reported a significant 36% year-on-year (YoY) increase in revenue, reaching ₹2,603 crore (₹26.03 billion) for the second quarter of fiscal year 2027 (Q2 FY27).
This strong performance was driven by robust growth across all business segments, with the US market showing a remarkable 77% YoY increase in revenue to ₹1,003 crore (₹10.03 billion). The India Branded Business also demonstrated healthy growth, with a 14% YoY increase to ₹725 crore (₹7.25 billion). The API business grew by 39% YoY to ₹436 crore (₹4.36 billion), while the Ex-US formulation business saw a 12% YoY increase to ₹440 crore (₹4.40 billion).
Profit After Tax (PAT) surged by 81% YoY to ₹335 crore (₹3.35 billion), and EBITDA margins expanded by 520 basis points to 22%. Gross margins improved by 70 basis points to 73.7%. The company maintained its R&D spend at 8% of revenue, focusing on building its specialty portfolio and US Branded platform.
For the half-year ended September 30, 2026 (H1 FY27), total revenue stood at ₹4,753 crore (₹47.53 billion), a 31% increase YoY. PAT for H1 FY27 was ₹508 crore (₹5.08 billion), a 50% increase YoY.
The company also highlighted its manufacturing capabilities, with multiple facilities audited by USFDA and WHO, and a commitment to ESG goals, including a Net Zero target by 2050 and water neutrality by 2027.
What to do with a filing like this
Alembic Pharmaceuticals Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Alembic Pharmaceuticals Limited. Read the original for the full detail.